The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | Key unmet needs in the management of patients with MPNs: a real-world perspective
Marta Sobas, MD, PhD, Wroclaw Medical University, Wroclaw, Poland, highlights key unmet needs in patients with myeloproliferative neoplasms (MPNs) from a real-world perspective. She notes the importance of preventing progression to myelofibrosis (MF) and acute myeloid leukemia (AML), and the need for disease-modifying agents. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
